SVB Securities analyst Jonathan Chang maintained a Buy rating on Vincerx Pharma Inc (VINC – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $1.48.
According to TipRanks, Chang is an analyst with an average return of -10.0% and a 30.06% success rate. Chang covers the Healthcare sector, focusing on stocks such as ImmunoGen, Replimune Group, and Immatics.
Currently, the analyst consensus on Vincerx Pharma Inc is a Strong Buy with an average price target of $6.00.
See today’s best-performing stocks on TipRanks >>
Based on Vincerx Pharma Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $16.42 million. In comparison, last year the company had a GAAP net loss of $6.28 million
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VINC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LifeSci Acquisition Corp is a blank check company.
Read More on VINC:
- Morgan Stanley Sticks to Their Hold Rating for Arhaus (ARHS)
- Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering
- Telsey Advisory Keeps Their Buy Rating on Holley (HLLY)
- Save Foods Expands Global Footprint as it Kickstarts Seven Commercial Pilots with Leading Exporters in Peru
- Aldebaran Announces Closing of Strategic Investment by South32
